<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id><journal-id journal-id-type="iso-abbrev">Med. Sci. Monit</journal-id><journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id><journal-title-group><journal-title>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research</journal-title></journal-title-group><issn pub-type="ppub">1234-1010</issn><issn pub-type="epub">1643-3750</issn><publisher><publisher-name>International Scientific Literature, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28174415</article-id><article-id pub-id-type="pmc">5312245</article-id><article-id pub-id-type="doi">10.12659/MSM.900059</article-id><article-id pub-id-type="publisher-id">900059</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Jinwei</given-names></name><xref ref-type="author-notes" rid="fn5-medscimonit-23-704">E</xref><xref ref-type="author-notes" rid="fn6-medscimonit-23-704">F</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Jun</given-names></name><xref ref-type="author-notes" rid="fn2-medscimonit-23-704">B</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Qiang</given-names></name><xref ref-type="author-notes" rid="fn3-medscimonit-23-704">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-23-704">D</xref></contrib><contrib contrib-type="author"><name><surname>Yue</surname><given-names>Chen</given-names></name><xref ref-type="author-notes" rid="fn3-medscimonit-23-704">C</xref><xref ref-type="author-notes" rid="fn5-medscimonit-23-704">E</xref></contrib><contrib contrib-type="author"><name><surname>Pei</surname><given-names>Fuxing</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-23-704">A</xref><xref ref-type="author-notes" rid="fn7-medscimonit-23-704">G</xref><xref ref-type="corresp" rid="c1-medscimonit-23-704"/></contrib><aff id="af1-medscimonit-23-704">Department of Orthopedic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China</aff></contrib-group><author-notes><corresp id="c1-medscimonit-23-704">Corresponding Author: Fuxing Pei, e-mail: <email>peifuxinghuaxi@126.com</email></corresp><fn id="fn1-medscimonit-23-704"><label>A</label><p>Study Design</p></fn><fn id="fn2-medscimonit-23-704"><label>B</label><p>Data Collection</p></fn><fn id="fn3-medscimonit-23-704"><label>C</label><p>Statistical Analysis</p></fn><fn id="fn4-medscimonit-23-704"><label>D</label><p>Data Interpretation</p></fn><fn id="fn5-medscimonit-23-704"><label>E</label><p>Manuscript Preparation</p></fn><fn id="fn6-medscimonit-23-704"><label>F</label><p>Literature Search</p></fn><fn id="fn7-medscimonit-23-704"><label>G</label><p>Funds Collection</p></fn></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>08</day><month>2</month><year>2017</year></pub-date><volume>23</volume><fpage>704</fpage><lpage>711</lpage><history><date date-type="received"><day>13</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>07</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Med Sci Monit, 2017</copyright-statement><copyright-year>2017</copyright-year><license><license-p>This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)</license-p></license></permissions><abstract><sec><title>Background</title><p>This study aimed to assess whether the efficacy of tranexamic acid (TXA) would be altered when rivaroxaban or enoxaparin was used for thromboprophylaxis in primary total knee replacement (TKR). It was hypothesized that the hemostatic effect of TXA would be better with the use of enoxaparin.</p></sec><sec><title>Material/Methods</title><p>A randomized clinical trial was conducted on 194 patients undergoing primary TKR for osteoarthritis. An intravenous dose of 15 mg/kg (TXA) and 1 g topical TXA were used. Patients randomly received enoxaparin or rivaroxaban prophylaxis when the drainage was less than 30 ml/h 6&#x02013;8 h postoperatively. The primary endpoint was hidden blood loss (HBL). Indexes of total blood loss drainage, hemoglobin drop, transfusion, range of motion (ROM), HSS score, VAS pain score, knee swelling, length of hospital stay (LOHS), incidence of venous thromboembolism, major/minor bleeding, and wound complications were also compared between the groups.</p></sec><sec><title>Results</title><p>More than 80% of patients initiated anticoagulation within 6 h postoperatively. No statistically significance difference was detected in terms of HBL (679.0&#x000b1;205.6 <italic>vs.</italic> 770.5&#x000b1;206.1, p=.062) or other bleeding index, ROM, or LOHS. The motion VAS pain score and knee swelling (16.7% <italic>vs.</italic> 6.1%, p=.021) were significantly lower, and HSS score at discharge was higher in the enoxaparin group. The rivaroxaban group had less asymptomatic deep venous (4.1% <italic>vs.</italic> 0%, p=.121) and muscular venous thrombosis (2.1% <italic>vs.</italic> 9.2%, p=.033); more ecchymosis (13.5% <italic>vs.</italic> 10.2%, p=.472), and wound complications (13.5% <italic>vs.</italic> 6.1%, p=.082). No episodes of transfusion, pulmonary embolism, or major bleeding occurred in either group.</p></sec><sec><title>Conclusions</title><p>More attention should be paid to the increased risk of wound complications and knee swelling associated with rivaroxaban, although the hidden blood loss was similar in both groups.</p></sec></abstract><kwd-group><title>MeSH Keywords</title><kwd>Anticoagulants</kwd><kwd>Antifibrinolytic Agents</kwd><kwd>Arthroplasty, Replacement, Knee</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>One of the most common and successful surgeries to treat end-stage knee disease is total knee replacement (TKR), which can relieve pain, improve function, and improve the quality of life. It is estimated that the demand for primary TKR will grow by 673% to 3.48 million procedures by 2030 in United States [<xref rid="b1-medscimonit-23-704" ref-type="bibr">1</xref>]. But the substantial blood loss and allogeneic blood transfusion requirements associated with TKR are the major concerns for joint surgeons. Because of the concerns regarding blood supply, cost, and inappropriate use, efforts have been made by health care providers to minimize blood loss and transfusion requirement [<xref rid="b2-medscimonit-23-704" ref-type="bibr">2</xref>]. Previous studies have shown that perioperative blood loss may be due to surgical trauma and subsequent fibrinolysis. Furthermore, ischemia reperfusion injury (IRI) after deflating the tourniquet may induce neutrophil aggregation and activate a series of inflammatory mediators, leading to t-PA release, which enhances the fibrinolysis activated by surgical trauma [<xref rid="b3-medscimonit-23-704" ref-type="bibr">3</xref>,<xref rid="b4-medscimonit-23-704" ref-type="bibr">4</xref>]. On the basis of the findings mentioned above, tranexamic acid (TXA), an anti-fibrinolytic agent, has been successfully applied in TKR with promising results [<xref rid="b5-medscimonit-23-704" ref-type="bibr">5</xref>&#x02013;<xref rid="b8-medscimonit-23-704" ref-type="bibr">8</xref>], but there is no consensus about its safety profile.</p><p>Patients undergoing major orthopedic surgery, especially lower limb joint replacement, are inherently at high risk of venous thromboembolism (VTE). There is a consensus on the application of thromboprophylaxis following TKR. Recently, both the American Academy of Orthopedic Surgeons (AAOS) and the American College of Chest Physicians (ACCP) have developed new evidence-based guidelines for venous thromboembolic prophylaxis after total joint arthroplasty [<xref rid="b9-medscimonit-23-704" ref-type="bibr">9</xref>,<xref rid="b10-medscimonit-23-704" ref-type="bibr">10</xref>]. Anti-fibrinolysis and anticoagulation are reconcilable contradictions. To take precautions against both the blood loss and VTE after total joint arthroplasty, the selection of proper regimens is actually a balance between efficacy and safety. We should be alert to the risk of postoperative VTE associated with antifibrinolytic agents, as well as the risk of bleeding caused by anticoagulants. Most important is how to choose the appropriate timing of the first dose of anticoagulants. Hence, we need to formulate an appropriate strategy to determine when best to initiate anticoagulation for balancing anti-fibrinolysis and anticoagulation [<xref rid="b11-medscimonit-23-704" ref-type="bibr">11</xref>]. However, there are few studies on this topic.</p><p>At present, LMWH and factor Xa inhibitor are most commonly used in TKR. In view of the excellent efficacy and safety profile, LMWH has been recommended as the first choice for VTE in the ACCP guideline (9<sup>th</sup> edition, 2B) [<xref rid="b9-medscimonit-23-704" ref-type="bibr">9</xref>]. In most studies, LMWH was used as the antithrombotic prophylaxis after TXA, which was used for bleeding prophylaxis. Due to different function mechanisms, new oral anticoagulants have distinct efficacy and safety profiles, and some researchers indicated that different anticoagulants may alter the efficacy of TXA in reducing blood loss [<xref rid="b12-medscimonit-23-704" ref-type="bibr">12</xref>]. However, few study have verified the interaction with TXA. Therefore, we carried out this pilot study to explore an appropriate strategy to initiate anticoagulation for balancing anti-fibrinolysis and anticoagulation, as well as to assess whether the efficacy of TXA would be altered when rivaroxaban or enoxaparin was used for thromboprophylaxis in primary TKR. It was hypothesized that the hemostatic effect of TXA would be better with the use of enoxaparin.</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><sec sec-type="methods"><title>Inclusion and exclusion criteria/study design</title><p>This prospective, randomized, clinical trial was performed on patients who were scheduled for primary unilateral TKR from August 2015 to March 2016. Before starting this trial, the study protocol was approved by the Institutional Review Board (IRB) of the West China Medical Center of Sichuan University (No. 268/2012; 7 January 2013). Written informed consent and research authorizations were obtained prior to surgery from all participants.</p><p>All patients, aged 18 years and older, who were scheduled for primary unilateral TKR for osteoarthritis were considered eligible for inclusion in the trial. Exclusion criteria for both groups included patients with cardiovascular problems (history of myocardial infraction, angina, and atrial fibrillation), cerebrovascular conditions (history of previous stroke), thromboembolic disorders (history of deep-vein thrombosis [DVT] or pulmonary embolism [PE]), clotting disorders, discontinuation of oral NSAID less than 1 week before, active peptic ulcer or organic damage with bleeding tendency, anticoagulants intake, and known allergy to TXA, LMWH, or rivaroxaban.</p><p>Recruited patients were randomly assigned by computer-generated randomization to 2 groups to receive either LMWH (group A) or rivaroxaban (group B). Patient assignments were prepared by a research statistician and were placed into sequentially numbered opaque sealed envelopes, which were opened after wound closure. The surgeons, patients, and nursing staff were not blinded to the treatment arm because of the nature of different thrombophylaxis protocols, but the data collector and analyst were blinded.</p><p>During the recruitment period, 210 patients were scheduled to have a primary unilateral TKR in our institution because of osteoarthritis, but 10 were ineligible, 2 declined to participate, and 2 patients chose conservative treatment. The remaining 196 patients were randomized to group A (98 patients) and group B (98 patients). Finally, 2 patients (2%) in group B were lost to follow-up because of financial barriers and time commitment (<xref ref-type="fig" rid="f1-medscimonit-23-704">Figure 1</xref>). The 2 groups were comparable in baseline characteristics (<xref ref-type="table" rid="t1-medscimonit-23-704">Table 1</xref>).</p></sec><sec><title>Anesthesia and surgery</title><p>All the operations were performed under general anesthesia by a single surgeon (F.X. Pei). TKR was performed in the standard way, using a middle skin incision, a standard medial parapatellar approach, and a measured resection technique. Intramedullary guides were used for all femoral preparation and extramedullary guides were used for tibial preparation. Autologous bone was used to fill the femoral medullary canal before implant cementation. All patients received a surgeon-selected cemented posterior-stabilized prosthetic design with patellar resurfacing. A tourniquet was applied to all the patients with a strategy of inflating before incision and deflating after compressing the lower limb with 2 elastic bandages under control at 100 mmHg above systolic pressure. Hemostasis was initiated, which included an intravenous dose of 15 mg/kg TXA administrated 5&#x02013;15 min before tourniquet deflation, and 1 g TXA was injected into the articular cavity through the drainage tube. The drainage tube remained clamped for 2 h and was removed the next morning postoperatively.</p></sec><sec><title>Pain management and rehabilitation protocol</title><p>All the patients took Diclofenac Sodium Enteric-coated tablets orally with a regular dose of 50 mg bid for postoperative pain management in addition to the intraoperative periarticular injection of Ropivacaine. All patients were subjected to a similar physical rehabilitation protocol in which dorsal and plantar flexion, as well as quadriceps muscle strength exercises, were initiated upon awakening from anesthesia. All the patients were mobilized with support using a walker on postoperative day (POD) 1. Active knee flexion and extension exercise were started on POD 1. The criteria for discharge included a knee flexion of at least 100&#x000b0; and a knee extension of at least 0&#x000b0;.</p></sec><sec><title>Thromboprophylaxis protocol</title><p>A combination of physical prophylaxis and chemoprophylaxis was used. An intermittent foot slope pump system was used as a routine practice to prevent DVT before walking. After the application of TXA, all patients were started on chemical DVT prophylaxis when drainage was less than 30 ml/h 6&#x02013;8 h postoperatively. In group A, a full dose of enoxaparin (0.4 ml 4000IU; Clexane, Sanofi-Aventis, France) was subcutaneously administered and repeated at 24-h intervals in the subsequent days for 15 days. In group B, 10 mg of oral rivaroxaban (Xarelto, Bayer, Germany) once daily was given to the patients for 15 days.</p></sec><sec><title>Antibiotic prophylaxis</title><p>Cefuroxime or clindamycin were used as perioperative antibiotic prophylaxis, with the first dose started at 30 min prior to surgery and repeated at 12-h intervals for 24 h.</p></sec><sec><title>Outcome measurements</title><p>Measurements were completed during the inpatient hospital stay. Preoperatively, patient demographics, medical history, and concomitant medication were registered. Renal and hepatic function tests were performed. Hemoglobin (Hb), hematocrit (Hct), activated partial thromboplastin time (APTT), and prothrombin time (PT) were measured preoperatively on POD 1 and POD 3.</p><p>As the primary outcome, hidden blood loss (HBL) was defined as bleeding into the tissues, residual blood in joints, and loss due to hemolysis, which can be calculated by detecting difference between total blood loss (TBL) and measured blood loss. Because of the use of a tourniquet, the intraoperative blood loss was negligible, so HBL was equal to TBL minus the volume of drainage. TBL was calculated according to the Gross formula [<xref rid="b13-medscimonit-23-704" ref-type="bibr">13</xref>]. The volume of drainage was recorded carefully every hour by a nurse who was not involved in our study. The time of the first dose of anticoagulant prophylaxis against VTE was recorded.</p><p>Color Doppler ultrasonography was routinely performed for bilateral femoral veins, superficial veins, popliteal veins, and calf veins (peroneal, posterior tibial, anterior tibial veins, and calf muscle veins) by a skilled physician who was not involved in this study, before surgery and 7 days and 14 days after surgery. If DVT was clinically suspended (limb swelling, pain, or Homman&#x02019;s sign positive), the Doppler ultrasound was applied immediately. PE was screened by symptoms. If symptoms of shortness of breath, chest pain, light headedness, or chest congestion were present, enhanced spiral computed tomography (CT) was performed immediately. All the patients returned to the clinic at 2, 4, and 12 weeks postoperatively. After 3 months, patients were phoned and asked whether they had been diagnosed or treated with DVT or PE in other hospitals. All mortality and readmission events were recorded during the follow-up period.</p><p>Major bleeding events and clinically relevant non-major bleeding events were defined according to a previous study [<xref rid="b14-medscimonit-23-704" ref-type="bibr">14</xref>]. During hospital stay and follow-up period, their wound healing and wound complications (including wound leakage, hematoma, surgical site infection [<xref rid="b15-medscimonit-23-704" ref-type="bibr">15</xref>], and deep infection) were observed and recorded. Wound leakage was defined as oozing of the surgical wound and drain site until 48 h.</p><p>Other measurements, including swelling ratio, the length of hospital stay (LOHS), motion VAS pain score, range of motion (ROM), HSS score, and patient satisfaction, were compared. Swelling was defined as the circumference of the operative knee being 3 cm larger than the circumference of the contralateral limb on POD 3. VAS pain score was assessed when the knee flexed by 45&#x000b0; from POD 1 to POD 4. All the outcomes mentioned above, including complications, swelling ratio, VAS pain score, ROM, hospital for special surgery knee score (HSS score), and satisfaction, were measured by a colleague who was not aware of the randomization.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>We considered a 100 ml reduction of hidden blood loss in the LWMH group compared to the rivaroxaban group as clinically significant. We assumed an alpha risk of 0.05, and a beta risk of 0.2. The number of patients required for each group was 93, or 186 in total. The software used for this calculation was G-Power.</p><p>All data management and statistical analyses were performed using SPSS version 19.0 software (SPSS Inc., USA). Continuous variables are presented as mean &#x000b1; standard deviation, and the independent <italic>t</italic> test was used to compare 2 groups. Pearson chi-square test or Fisher exact test were used to analyze the categorical variables. A p value of &#x0003c;.05 was considered significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>According to the predefined criteria, the average time of initial anticoagulation was 6 h postoperatively (6.14 <italic>vs.</italic> 6.21, p=.318). The percentage of starting chemoprophylaxis within 6 h postoperatively was more than 80% in either group. The drainage volume at the time which we chose to initiate anticoagulation was similar in both groups. No statistical significance was detected in terms of 24-h drainage, TBL, HBL, Hb drop, or Hct drop on POD 3. The PT and APTT were prolonged when compared with the preoperative level, and it was more obvious when rivaroxaban was used as antithrombotic prophylaxis against VTE (<xref ref-type="table" rid="t2-medscimonit-23-704">Table 2</xref>).</p><p>The patients in group A had significantly lower VAS pain score on POD 1 (2.14&#x000b1;0.88 <italic>vs.</italic> 2.65&#x000b1;1.13, p=.001), POD 2 (2.07&#x000b1;0.46 <italic>vs.</italic> 2.31&#x000b1;0.80, p=.013), POD 3 (1.99&#x000b1;0.53 <italic>vs.</italic> 2.14&#x000b1;0.38, p=.022), and POD 4 (1.95&#x000b1;0.42 <italic>vs.</italic> 2.12&#x000b1;0.33, p=.001). Similarly, the swelling ratio was lower in group A (6.1% <italic>vs.</italic> 16.7%, p=.021). The mean LOHS in group A was 6.1&#x000b1;1.7 days, 6.3&#x000b1;2.9 days in group B, and the difference was not significant (p=.729). The ROM at discharge was comparable in the 2 groups. The HSS score at discharge was significantly higher in group A (90.83&#x000b1;1.34 <italic>vs.</italic> 89.48&#x000b1;3.21, p&#x0003c;.001, <xref ref-type="table" rid="t3-medscimonit-23-704">Table 3</xref>).</p><p>No episode of PE, mortality, or major bleeding events occurred in either group. There were 4 patients with DVT (3 posterior tibial vein, 1 peroneal vein) in group A, 0 patients in group B, and the difference was not statistically significant (p=.121). Nine patients in group A and 2 patients in group B were diagnosed as having calf muscular vein thrombosis, with statistical significance (p=.033). All the VTE was asymptomatic and detected by routine ultrasonic examination postoperatively. The mean days of VTE was 4. Of the total, 13 were females and 2 were males, the mean age was 69.2 years, mean BMI was 26.6 kg/m<sup>2</sup>, and mean ASA score was 2. Group B had higher incidence of subcutaneous ecchymosis in the affected extremities, but without statistical significance (13.5% <italic>vs.</italic> 10.2%, p=.472). Thirteen patients developed wound complications (11 wound leakage, 1 hematoma, 1 surgical site infection) in group B, and 6 patients (6 wound leakage) in group A, and the difference was not statistically significant (13.5% <italic>vs.</italic> 6.1%, p=.082, <xref ref-type="table" rid="t4-medscimonit-23-704">Table 4</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Patients undergoing TKR are inherently at high risk of developing VTE because the procedure exposes patients to each part of Virchow&#x02019;s triad: stasis of blood flow, vascular endothelial damage, and hypercoagulability of blood during the operative period [<xref rid="b16-medscimonit-23-704" ref-type="bibr">16</xref>,<xref rid="b17-medscimonit-23-704" ref-type="bibr">17</xref>]. The main mechanism of TXA is to inhibit the activation of plasminogen, reduce the breakdown of fibrin, stabilize the clot, and thus reduce blood loss. On the other hand, TXA also inhibits the thrombolysis forming on the damaged vascular endothelial, so it may promote blood clots extending proximally. Reiker&#x000e5;s et al. [<xref rid="b18-medscimonit-23-704" ref-type="bibr">18</xref>] found the local thrombogenic and fibrinolytic activity was activated as soon as deflating the tourniquet, then systemic activation of the clotting cascade was activated in 4 h postoperatively. Maynard et al. [<xref rid="b19-medscimonit-23-704" ref-type="bibr">19</xref>] reported that 47% of DVTs occurred on POD 1 after TKR. Therefore, earlier anticoagulation is vital for prevention of VTE [<xref rid="b20-medscimonit-23-704" ref-type="bibr">20</xref>]. However, the risk of bleeding is co-existent with VTE because of the hyper-fibrinolysis resulting from surgical trauma and tourniquet use. According to a kinetics study [<xref rid="b21-medscimonit-23-704" ref-type="bibr">21</xref>], hyper-fibrinolysis peaked at 6 h postoperatively, which would last for 18 h. Thus, earlier coagulation should balance efficacy and safety, especially the safety profile, which is why we chose the HBL as primary outcome. But with fibrinolytic activity inhibited by TXA, it is important to consider how to determine the appropriate time at which to start antithrombotic prophylaxis, which would not increase the risk of postoperative VTE while minimizing the loss of blood, and how to maintain the balance between anti-fibrinolysis and anticoagulant [<xref rid="b11-medscimonit-23-704" ref-type="bibr">11</xref>].</p><p>The timing of the first dose of anticoagulant prophylaxis against VTE after major orthopedic surgery is still controversial [<xref rid="b22-medscimonit-23-704" ref-type="bibr">22</xref>]. For patients receiving LMWH as thromboprophylaxis, although current guidelines (ACCP VTE guidelines, 9<sup>th</sup> edition) recommend that the agent should be started either &#x02265;12 h preoperatively or &#x02265;12 h postoperatively to balance the effectiveness and safety, the situation in Europe and North America differs [<xref rid="b23-medscimonit-23-704" ref-type="bibr">23</xref>]. In a meta-regression analysis conducted by Tribout et al. [<xref rid="b24-medscimonit-23-704" ref-type="bibr">24</xref>], the results revealed that a more pragmatic and balanced approach would be starting thromboprophylaxis 6&#x02013;8 h postoperatively. In our study, the main reason why we initiated anticoagulation 6&#x02013;8 h postoperatively according to the change of drainage volume was that previous studies revealed that approximately 65% of visible blood loss occurred within 6 h postoperatively [<xref rid="b25-medscimonit-23-704" ref-type="bibr">25</xref>,<xref rid="b26-medscimonit-23-704" ref-type="bibr">26</xref>]. Lin et al. also found TXA can only reduce the amount of postoperative drainage within 6 h; however, after 6 h, the amount of drainage was similar in both the TXA group and control group [<xref rid="b27-medscimonit-23-704" ref-type="bibr">27</xref>]. Hence, we assumed that the overt bleeding stopped when the drainage was less than 30 ml per h, then anticoagulation should be started. The results in this study also showed the drainage within 6 h accounted for 57% of total drainage, and the ratio of patients who needed anticoagulant at postoperative 6 h was as high as 87%. According to the present study and our preliminary results [<xref rid="b28-medscimonit-23-704" ref-type="bibr">28</xref>], the method by which the timing of anticoagulation was decided to maintain balance between anticoagulation and anti-fibrinolysis was safe. However, because of the lack of a control group, further prospective studies are needed to evaluate whether there was a difference in terms of efficacy and safety profile in different timing of anticoagulation with the same anticoagulants.</p><p>Enoxaparin, an indirect factor Xa inhibitor, is the criterion standard to prevent VTE in major orthopedic surgery. Considering the excellent efficacy and safety profile, enoxaparin was strongly recommended in the ACCP guideline (9<sup>th</sup> edition, 2B). In recent years, rivaroxaban, a direct factor Xa inhibitor, has been put in the spotlight. A net meta-analysis [<xref rid="b29-medscimonit-23-704" ref-type="bibr">29</xref>] involving 16 trials of rivaroxaban, apixaban, and dabigatran compared with enoxaparin for prophylaxis against VTE after total hip or knee replacement showed the higher efficacy of new anticoagulants and a higher bleeding tendency. Nevertheless, the trials did not measure the surgical outcomes, such as wound healing, drainage, or infection, which can compromise functional outcomes and increase the rate of transfusion, reoperation, and revision surgery. Moreover, LMWH was mostly used as prophylaxis against thromboembolism when TXA was used as prophylaxis against bleeding. Other chemoprophylaxis agents may alter the efficacy of TXA [<xref rid="b12-medscimonit-23-704" ref-type="bibr">12</xref>]. Therefore, we conducted this trial based on the hypothesis that the hemostatic effect of TXA would be better with the use of enoxaparin. In the current study, there was more HBL in the rivaroxaban group, although the difference was not significant. This may explain for the higher rate of swelling (16.7% <italic>vs</italic>. 2.1%, p=.021), higher VAS pain score, and lower HSS score in the rivaroxaban group.</p><p>Jameson et al. [<xref rid="b30-medscimonit-23-704" ref-type="bibr">30</xref>] performed a multicenter comparison of rivaroxaban and LMWH for thromboprophylaxis in 13 213 patients undergoing lower limb arthroplasty. The results revealed a lower risk of wound complications with the use of LMWH (OR=.72, p=.005), and more symptomatic DVT was observed (0.91% <italic>vs.</italic> 0.36%, p=.004). Another prospective cohort study [<xref rid="b31-medscimonit-23-704" ref-type="bibr">31</xref>] showed a greater risk of minor bleeding and wound complications with the use of rivaroxaban. Furthermore, Castillo et al. [<xref rid="b32-medscimonit-23-704" ref-type="bibr">32</xref>] reported the potential risk of spontaneous spinal subdural hematoma associated with rivaroxaban in non-valvular atrial fibrillation patients. Unfortunately, TXA was not taken into consideration. In Yen&#x02019;s retrospective study [<xref rid="b33-medscimonit-23-704" ref-type="bibr">33</xref>], a dose of 10 mg/kg TXA was intravenously given to 113 patients undergoing primary TKR. They found that no difference in postoperative Hb level, blood drainage, TBL, transfusion rate, or postoperative wound-related complications in the rivaroxaban group when compared with enoxaparin. Similarly, our results also indicated no increased perioperative bleeding. Post hoc power analysis of this trial showed a power of 88.4% to detect a significant difference (&#x003b1;= 0.05, 2-side) of HBL, which indicated the sample size was not too small and the trial did not lack the precision to provide reliable answers to the questions it was investigating. However, it is not adequately powered to detect a difference in terms of complications, and further studies with larger sample sizes are needed.</p><p>The strengths of this study include its prospective randomized nature, and the fact that it is the first preliminary exploration for the balance between anti-fibrinolysis and anticoagulation associated with TXA following primary TKR. In addition, it compared different anticoagulants in terms of their role in keeping the balance. The last but not the least, we also compared the function outcomes, including ROM, VAS pain score, and HSS score. We acknowledge several limitations needing further discussion. Because of the essentially different interventions, this study was not able to use blind methods, but as the data collector and analyst did not take part in the designing process of the study, so the theoretical measuring bias would not have an effect on the accuracy of the study&#x02019;s results.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>We conclude that initiation of sequential anticoagulation on the basis of drainage may be a pragmatic approach to balance anticoagulation and anti-fibrinolysis after the administration of TXA in primary TKR, according to the information available and the results of this study. More attention should be paid to the increased risk of wound complications and knee swelling associated with rivaroxaban, although the hidden blood loss was similar in both groups.</p></sec></body><back><ack><title>Acknowledgement</title><p>We thank the nursing staff from the Department of Orthopedic surgery, West China Hospital, and the patients for their support during the study period.</p></ack><fn-group><fn id="fn8-medscimonit-23-704"><p><bold>Source of support:</bold> This research was funded by the National Health and Family Planning Commission of the People&#x02019;s Republic of China (CN) Program (201302007)</p></fn><fn id="fn9-medscimonit-23-704" fn-type="COI-statement"><p><bold>Conflicts of interest statement</bold></p><p>All authors have no financial or personal relationships with other people or organizations that could inappropriately influence this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-medscimonit-23-704"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtz</surname><given-names>S</given-names></name><name><surname>Ong</surname><given-names>K</given-names></name><name><surname>Lau</surname><given-names>E</given-names></name><etal/></person-group><article-title>Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030</article-title><source>J Bone Joint Surg Am</source><year>2007</year><volume>89</volume><fpage>780</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">17403800</pub-id></element-citation></ref><ref id="b2-medscimonit-23-704"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alshryda</surname><given-names>S</given-names></name><name><surname>Sukeik</surname><given-names>M</given-names></name><name><surname>Sarda</surname><given-names>P</given-names></name><etal/></person-group><article-title>A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement</article-title><source>Bone Joint J</source><year>2014</year><volume>96-B</volume><fpage>1005</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">25086114</pub-id></element-citation></ref><ref id="b3-medscimonit-23-704"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahmy</surname><given-names>NR</given-names></name><name><surname>Patel</surname><given-names>DG</given-names></name></person-group><article-title>Hemostatic changes and postoperative deep-vein thrombosis associated with use of a pneumatic tourniquet</article-title><source>J Bone Joint Surg Am</source><year>1981</year><volume>63</volume><fpage>461</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">7204448</pub-id></element-citation></ref><ref id="b4-medscimonit-23-704"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klenerman</surname><given-names>L</given-names></name><name><surname>Chakrabarti</surname><given-names>R</given-names></name><name><surname>Mackie</surname><given-names>I</given-names></name><etal/></person-group><article-title>Changes in haemostatic system after application of a tourniquet</article-title><source>Lancet</source><year>1977</year><volume>1</volume><fpage>970</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">67466</pub-id></element-citation></ref><ref id="b5-medscimonit-23-704"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alshryda</surname><given-names>S</given-names></name><name><surname>Sarda</surname><given-names>P</given-names></name><name><surname>Sukeik</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tranexamic acid in total knee replacement: A systematic review and meta-analysis</article-title><source>J Bone Joint Surg Br</source><year>2011</year><volume>93</volume><fpage>1577</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">22161917</pub-id></element-citation></ref><ref id="b6-medscimonit-23-704"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Barrena</surname><given-names>E</given-names></name><name><surname>Ortega-Andreu</surname><given-names>M</given-names></name><name><surname>Padilla-Eguiluz</surname><given-names>NG</given-names></name><etal/></person-group><article-title>Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: A double-blind, randomized, controlled, noninferiority clinical trial</article-title><source>J Bone Joint Surg Am</source><year>2014</year><volume>96</volume><fpage>1937</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">25471907</pub-id></element-citation></ref><ref id="b7-medscimonit-23-704"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alshryda</surname><given-names>S</given-names></name><name><surname>Mason</surname><given-names>J</given-names></name><name><surname>Vaghela</surname><given-names>M</given-names></name><etal/></person-group><article-title>Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: A randomized controlled trial (TRANX-K)</article-title><source>J Bone Joint Surg Am</source><year>2013</year><volume>95</volume><fpage>1961</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">24196466</pub-id></element-citation></ref><ref id="b8-medscimonit-23-704"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Pei</surname><given-names>F</given-names></name></person-group><article-title>Combination of intravenous and topical application of tranexamic acid in primary total knee arthroplasty: A prospective randomized controlled trial</article-title><source>J Arthroplasty</source><year>2014</year><volume>29</volume><fpage>2342</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">25007725</pub-id></element-citation></ref><ref id="b9-medscimonit-23-704"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mont</surname><given-names>MA</given-names></name><name><surname>Jacobs</surname><given-names>JJ</given-names></name></person-group><article-title>AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty</article-title><source>J Am Acad Orthop Surg</source><year>2011</year><volume>19</volume><fpage>777</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">22134210</pub-id></element-citation></ref><ref id="b10-medscimonit-23-704"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falck-Ytter</surname><given-names>Y</given-names></name><name><surname>Francis</surname><given-names>CW</given-names></name><name><surname>Johanson</surname><given-names>NA</given-names></name><etal/></person-group><collab>American College of Chest Physicians</collab><article-title>Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9<sup>th</sup> ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</article-title><source>Chest</source><year>2012</year><volume>141</volume><fpage>e278S</fpage><lpage>325S</lpage><pub-id pub-id-type="pmid">22315265</pub-id></element-citation></ref><ref id="b11-medscimonit-23-704"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raveendran</surname><given-names>R</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name></person-group><article-title>Tranexamic acid: More evidence for its use in joint replacement surgery</article-title><source>Transfusion</source><year>2014</year><volume>54</volume><fpage>2</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">24405302</pub-id></element-citation></ref><ref id="b12-medscimonit-23-704"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>JN</given-names></name><name><surname>Spanyer</surname><given-names>JM</given-names></name><name><surname>Smith</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Comparison of intravenous versus topical tranexamic acid in total knee arthroplasty: A prospective randomized study</article-title><source>J Arthroplasty</source><year>2014</year><volume>29</volume><fpage>1528</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">24768543</pub-id></element-citation></ref><ref id="b13-medscimonit-23-704"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>JB</given-names></name></person-group><article-title>Estimating allowable blood loss: corrected for dilution</article-title><source>Anesthesiology</source><year>1983</year><volume>58</volume><fpage>277</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">6829965</pub-id></element-citation></ref><ref id="b14-medscimonit-23-704"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veen</surname><given-names>Lv</given-names></name><name><surname>van Raay</surname><given-names>JJ</given-names></name><name><surname>Gerritsma-Bleeker</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Direct treatment comparison of DAbigatran and rivaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: Design of a randomised pilot study (DARINA)</article-title><source>BMJ Open</source><year>2013</year><volume>3</volume><issue>1</issue><comment>pii: e002218</comment></element-citation></ref><ref id="b15-medscimonit-23-704"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangram</surname><given-names>AJ</given-names></name><name><surname>Horan</surname><given-names>TC</given-names></name><name><surname>Pearson</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Guideline for prevention of surgical site infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee</article-title><source>Am J Infect Control</source><year>1999</year><volume>27</volume><fpage>97</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">10196487</pub-id></element-citation></ref><ref id="b16-medscimonit-23-704"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>FA</given-names><suffix>Jr</suffix></name><name><surname>Spencer</surname><given-names>FA</given-names></name></person-group><article-title>Risk factors for venous thromboembolism</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>I9</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">12814980</pub-id></element-citation></ref><ref id="b17-medscimonit-23-704"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izumi</surname><given-names>M</given-names></name><name><surname>Ikeuchi</surname><given-names>M</given-names></name><name><surname>Aso</surname><given-names>K</given-names></name><etal/></person-group><article-title>Less deep vein thrombosis due to transcutaneous fibular nerve stimulation in total knee arthroplasty: A randomized controlled trial</article-title><source>Knee Surg Sports Traumatol Arthrosc</source><year>2015</year><volume>23</volume><issue>11</issue><fpage>3317</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">24957913</pub-id></element-citation></ref><ref id="b18-medscimonit-23-704"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiker&#x000e5;s</surname><given-names>O</given-names></name><name><surname>Clementsen</surname><given-names>T</given-names></name></person-group><article-title>Time course of thrombosis and fibrinolysis in total knee arthroplasty with tourniquet application. Local versus systemic activations</article-title><source>J Thromb Thrombolysis</source><year>2009</year><volume>28</volume><fpage>425</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">19067121</pub-id></element-citation></ref><ref id="b19-medscimonit-23-704"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maynard</surname><given-names>MJ</given-names></name><name><surname>Sculco</surname><given-names>TP</given-names></name><name><surname>Ghelman</surname><given-names>B</given-names></name></person-group><article-title>Progression and regression of deep vein thrombosis after total knee arthroplasty</article-title><source>Clin Orthop Relat Res</source><year>1991</year><volume>273</volume><fpage>125</fpage><lpage>30</lpage></element-citation></ref><ref id="b20-medscimonit-23-704"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borgen</surname><given-names>PO</given-names></name><name><surname>Dahl</surname><given-names>OE</given-names></name><name><surname>Reiker&#x000e5;s</surname><given-names>O</given-names></name></person-group><article-title>Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis</article-title><source>Clin Orthop Relat Res</source><year>2012</year><volume>470</volume><fpage>2591</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">22476844</pub-id></element-citation></ref><ref id="b21-medscimonit-23-704"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blani&#x000e9;</surname><given-names>A</given-names></name><name><surname>Bellamy</surname><given-names>L</given-names></name><name><surname>Rhayem</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Duration of postoperative fibrinolysis after total hip or knee replacement: A laboratory follow-up study</article-title><source>Thromb Res</source><year>2013</year><volume>131</volume><fpage>e6</fpage><lpage>e11</lpage><pub-id pub-id-type="pmid">23195143</pub-id></element-citation></ref><ref id="b22-medscimonit-23-704"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raskob</surname><given-names>GE</given-names></name><name><surname>Hirsh</surname><given-names>J</given-names></name></person-group><article-title>Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery</article-title><source>Chest</source><year>2003</year><volume>124</volume><fpage>379S</fpage><lpage>85S</lpage><pub-id pub-id-type="pmid">14668421</pub-id></element-citation></ref><ref id="b23-medscimonit-23-704"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname><given-names>JR</given-names></name><name><surname>Pensak</surname><given-names>MJ</given-names></name></person-group><article-title>Prevention of venous thromboembolic disease after total hip and knee arthroplasty</article-title><source>J Bone Joint Surg Am</source><year>2013</year><volume>95</volume><fpage>1801</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">24088973</pub-id></element-citation></ref><ref id="b24-medscimonit-23-704"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tribout</surname><given-names>B</given-names></name><name><surname>Colin-Mercier</surname><given-names>F</given-names></name></person-group><article-title>New versus established drugs in venous thromboprophylaxis: Efficacy and safety considerations related to timing of administration</article-title><source>Am J Cardiovasc Drugs</source><year>2007</year><volume>7</volume><fpage>1</fpage><lpage>15</lpage></element-citation></ref><ref id="b25-medscimonit-23-704"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senthil Kumar</surname><given-names>G</given-names></name><name><surname>Von Arx</surname><given-names>OA</given-names></name><name><surname>Pozo</surname><given-names>JL</given-names></name></person-group><article-title>Rate of blood loss over 48 hours following total knee replacement</article-title><source>Knee</source><year>2005</year><volume>12</volume><fpage>307</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15990313</pub-id></element-citation></ref><ref id="b26-medscimonit-23-704"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>N</given-names></name><name><surname>Padmanabhan</surname><given-names>V</given-names></name><name><surname>Mullaji</surname><given-names>A</given-names></name></person-group><article-title>Comparison between two methods of drain clamping after total knee arthroplasty</article-title><source>Arch Orthop Trauma Surg</source><year>2005</year><volume>125</volume><fpage>381</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">15902479</pub-id></element-citation></ref><ref id="b27-medscimonit-23-704"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>PC</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>WS</given-names></name><etal/></person-group><article-title>Does tranexamic acid save blood in minimally invasive total knee arthroplasty?</article-title><source>Clin Orthop Relat Res</source><year>2011</year><volume>469</volume><fpage>1995</fpage><lpage>2002</lpage><pub-id pub-id-type="pmid">21286886</pub-id></element-citation></ref><ref id="b28-medscimonit-23-704"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>P</given-names></name><etal/></person-group><article-title>Does tranexamic acid alter the risk of thromboembolism following primary total knee arthroplasty with sequential earlier anticoagulation? A large, single center, prospective cohort study of consecutive cases</article-title><source>Thromb Res</source><year>2015</year><volume>136</volume><fpage>234</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">26026635</pub-id></element-citation></ref><ref id="b29-medscimonit-23-704"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-Outes</surname><given-names>A</given-names></name><name><surname>Terleira-Fern&#x000e1;ndez</surname><given-names>AI</given-names></name><name><surname>Su&#x000e1;rez-Gea</surname><given-names>ML</given-names></name><name><surname>Vargas-Castrill&#x000f3;n</surname><given-names>E</given-names></name></person-group><article-title>Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: Systematic review, meta-analysis, and indirect treatment comparisons</article-title><source>BMJ</source><year>2012</year><volume>344</volume><fpage>e3675</fpage><pub-id pub-id-type="pmid">22700784</pub-id></element-citation></ref><ref id="b30-medscimonit-23-704"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jameson</surname><given-names>SS</given-names></name><name><surname>Rymaszewska</surname><given-names>M</given-names></name><name><surname>Hui</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty</article-title><source>J Bone Joint Surg Am</source><year>2012</year><volume>94</volume><fpage>1554</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">22832942</pub-id></element-citation></ref><ref id="b31-medscimonit-23-704"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sindali</surname><given-names>K</given-names></name><name><surname>Rose</surname><given-names>B</given-names></name><name><surname>Soueid</surname><given-names>H</given-names></name><etal/></person-group><article-title>Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing</article-title><source>Eur J Orthop Surg Traumatol</source><year>2013</year><volume>23</volume><fpage>481</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">23412293</pub-id></element-citation></ref><ref id="b32-medscimonit-23-704"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>JM</given-names></name><name><surname>Afanador</surname><given-names>HF</given-names></name><name><surname>Manjarrez</surname><given-names>E</given-names></name><name><surname>Morales</surname><given-names>XA</given-names></name></person-group><article-title>Non-traumatic spontaneous spinal subdural hematoma in a patient with non-valvular atrial fibrillation during treatment with rivaroxaban</article-title><source>Am J Case Rep</source><year>2015</year><volume>16</volume><fpage>377</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">26090890</pub-id></element-citation></ref><ref id="b33-medscimonit-23-704"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>SH</given-names></name><name><surname>Lin</surname><given-names>PC</given-names></name><name><surname>Kuo</surname><given-names>FC</given-names></name><name><surname>Wang</surname><given-names>JW</given-names></name></person-group><article-title>Thromboprophylaxis after minimally invasive total knee arthroplasty: A comparison of rivaroxaban and enoxaparin</article-title><source>Biomed J</source><year>2014</year><volume>37</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">25116715</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-medscimonit-23-704" position="float"><label>Figure 1</label><caption><p>Flow diagram of the study.</p></caption><graphic xlink:href="medscimonit-23-704-g001"/></fig><table-wrap id="t1-medscimonit-23-704" position="float"><label>Table 1</label><caption><p>Baseline characteristics.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Variables</th><th valign="bottom" align="center" rowspan="1" colspan="1">Group A (n=98)</th><th valign="bottom" align="center" rowspan="1" colspan="1">Group B (n=96)</th><th valign="bottom" align="center" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="middle" align="center" rowspan="1" colspan="1">66.8&#x000b1;7.4</td><td valign="middle" align="center" rowspan="1" colspan="1">65.2&#x000b1;5.5</td><td valign="middle" align="center" rowspan="1" colspan="1">0.081</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Female (%)</td><td valign="middle" align="center" rowspan="1" colspan="1">86/98</td><td valign="middle" align="center" rowspan="1" colspan="1">74/96</td><td valign="middle" align="center" rowspan="1" colspan="1">0.051</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Height (m)</td><td valign="middle" align="center" rowspan="1" colspan="1">1.6&#x000b1;0.1</td><td valign="middle" align="center" rowspan="1" colspan="1">1.6&#x000b1;0.1</td><td valign="middle" align="center" rowspan="1" colspan="1">0.278</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Weight (Kg)</td><td valign="middle" align="center" rowspan="1" colspan="1">64.8&#x000b1;8.4</td><td valign="middle" align="center" rowspan="1" colspan="1">65.4&#x000b1;9.8</td><td valign="middle" align="center" rowspan="1" colspan="1">0.647</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">BMI (Kg/m<sup>2</sup>)</td><td valign="middle" align="center" rowspan="1" colspan="1">25.6&#x000b1;3.3</td><td valign="middle" align="center" rowspan="1" colspan="1">25.4&#x000b1;3.2</td><td valign="middle" align="center" rowspan="1" colspan="1">0.720</td></tr><tr><td colspan="4" valign="middle" align="left" rowspan="1">Co-morbidities</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Hypertension</td><td valign="middle" align="center" rowspan="1" colspan="1">28</td><td valign="middle" align="center" rowspan="1" colspan="1">22</td><td valign="middle" align="center" rowspan="1" colspan="1">0.368</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Coronary heart disease</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">2</td><td valign="middle" align="center" rowspan="1" colspan="1">0.683</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Diabetes</td><td valign="middle" align="center" rowspan="1" colspan="1">9</td><td valign="middle" align="center" rowspan="1" colspan="1">14</td><td valign="middle" align="center" rowspan="1" colspan="1">0.245</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">COPD</td><td valign="middle" align="center" rowspan="1" colspan="1">6</td><td valign="middle" align="center" rowspan="1" colspan="1">8</td><td valign="middle" align="center" rowspan="1" colspan="1">0.552</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">NSAIDs</td><td valign="middle" align="center" rowspan="1" colspan="1">27</td><td valign="middle" align="center" rowspan="1" colspan="1">23</td><td valign="middle" align="center" rowspan="1" colspan="1">0.567</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Aspirin</td><td valign="middle" align="center" rowspan="1" colspan="1">3</td><td valign="middle" align="center" rowspan="1" colspan="1">2</td><td valign="middle" align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ASA grade</td><td valign="middle" align="center" rowspan="1" colspan="1">1.6&#x000b1;0.7</td><td valign="middle" align="center" rowspan="1" colspan="1">1.7&#x000b1;0.8</td><td valign="middle" align="center" rowspan="1" colspan="1">0.647</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pre-Hb (g/L)</td><td valign="middle" align="center" rowspan="1" colspan="1">131.5&#x000b1;13.2</td><td valign="middle" align="center" rowspan="1" colspan="1">133.7&#x000b1;12.7</td><td valign="middle" align="center" rowspan="1" colspan="1">0.231</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pre-Hct (L/L)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.40&#x000b1;0.03</td><td valign="middle" align="center" rowspan="1" colspan="1">0.41&#x000b1;0.04</td><td valign="middle" align="center" rowspan="1" colspan="1">0.696</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pre-PLT (&#x000d7;10<sup>9</sup>/L)</td><td valign="middle" align="center" rowspan="1" colspan="1">188.1&#x000b1;51.9</td><td valign="middle" align="center" rowspan="1" colspan="1">196.6&#x000b1;65.8</td><td valign="middle" align="center" rowspan="1" colspan="1">0.051</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pre-APTT (s)</td><td valign="middle" align="center" rowspan="1" colspan="1">28.2&#x000b1;4.7</td><td valign="middle" align="center" rowspan="1" colspan="1">29.1&#x000b1;5.9</td><td valign="middle" align="center" rowspan="1" colspan="1">0.206</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pre-PT (s)</td><td valign="middle" align="center" rowspan="1" colspan="1">11.6&#x000b1;1.4</td><td valign="middle" align="center" rowspan="1" colspan="1">11.4&#x000b1;0.7</td><td valign="middle" align="center" rowspan="1" colspan="1">0.265</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pre-INR</td><td valign="middle" align="center" rowspan="1" colspan="1">1.02&#x000b1;0.06</td><td valign="middle" align="center" rowspan="1" colspan="1">1.02&#x000b1;0.05</td><td valign="middle" align="center" rowspan="1" colspan="1">0.913</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pre-D-dimer (ug/ml)</td><td valign="middle" align="center" rowspan="1" colspan="1">1.03&#x000b1;1.62</td><td valign="middle" align="center" rowspan="1" colspan="1">0.78&#x000b1;1.37</td><td valign="middle" align="center" rowspan="1" colspan="1">0.250</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">VAS score</td><td valign="middle" align="center" rowspan="1" colspan="1">5.04&#x000b1;1.61</td><td valign="middle" align="center" rowspan="1" colspan="1">5.26&#x000b1;1.51</td><td valign="middle" align="center" rowspan="1" colspan="1">0.328</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">ROM</td><td valign="middle" align="center" rowspan="1" colspan="1">77.09&#x000b1;17.26</td><td valign="middle" align="center" rowspan="1" colspan="1">79.22&#x000b1;18.11</td><td valign="middle" align="center" rowspan="1" colspan="1">0.403</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">HSS</td><td valign="middle" align="center" rowspan="1" colspan="1">46.02&#x000b1;10.74</td><td valign="middle" align="center" rowspan="1" colspan="1">42.93&#x000b1;12.07</td><td valign="middle" align="center" rowspan="1" colspan="1">0.061</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">PBV (ml)</td><td valign="middle" align="center" rowspan="1" colspan="1">3818.8&#x000b1;437.0</td><td valign="middle" align="center" rowspan="1" colspan="1">3919.7&#x000b1;604.</td><td valign="middle" align="center" rowspan="1" colspan="1">0.185</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Duration of operation (min)</td><td valign="middle" align="center" rowspan="1" colspan="1">71.5&#x000b1;7.1</td><td valign="middle" align="center" rowspan="1" colspan="1">69.8&#x000b1;6.8</td><td valign="middle" align="center" rowspan="1" colspan="1">0.09</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-medscimonit-23-704"><p>BMI &#x02013; body mass index; Pre-Hb &#x02013; preoperative hemoglobin; Pre-Hct &#x02013; preoperative hematocrit; Pre-PLT &#x02013; preoperative platelet; Pre-APTT &#x02013; preoperative activated partial thromboplastin time; Pre-PT &#x02013; preoperative prothrombin time; PBV (patient blood volume) was assessed according to the formula: PBV=k1 &#x000d7; height (m) + k2 &#x000d7; weight (kg) +k3. (k1=0.3669, k 2=0.03219, and k3=0.6041 for men; and k1=0.3561, k2=0.03308, and k3=0.1833 for women); COPD &#x02013; chronic obstructive pulmonary disease; NSAID &#x02013; non-steroidal anti-inflammatory drugs.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-medscimonit-23-704" position="float"><label>Table 2</label><caption><p>Primary outcomes.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Variables</th><th valign="bottom" align="center" rowspan="1" colspan="1">Group A (n=98)</th><th valign="bottom" align="center" rowspan="1" colspan="1">Group B (n=96)</th><th valign="bottom" align="center" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Time of initial anticoagulation</td><td valign="middle" align="center" rowspan="1" colspan="1">6.14&#x000b1;0.41</td><td valign="middle" align="center" rowspan="1" colspan="1">6.21&#x000b1;0.50</td><td valign="middle" align="center" rowspan="1" colspan="1">0.318</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Initial anticoagulation within 6 h (%)</td><td valign="middle" align="center" rowspan="1" colspan="1">87/98</td><td valign="middle" align="center" rowspan="1" colspan="1">81/96</td><td valign="middle" align="center" rowspan="1" colspan="1">0.368</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">TBL (ml)</td><td valign="middle" align="center" rowspan="1" colspan="1">865.9&#x000b1;302.9</td><td valign="middle" align="center" rowspan="1" colspan="1">958.8&#x000b1;393.8</td><td valign="middle" align="center" rowspan="1" colspan="1">0.067</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">HBL (ml)</td><td valign="middle" align="center" rowspan="1" colspan="1">679.0&#x000b1;205.6</td><td valign="middle" align="center" rowspan="1" colspan="1">770.5&#x000b1;206.1</td><td valign="middle" align="center" rowspan="1" colspan="1">0.062</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Drainage on the time of initiating anticoagulation (ml)</td><td valign="middle" align="center" rowspan="1" colspan="1">100.5&#x000b1;77.5</td><td valign="middle" align="center" rowspan="1" colspan="1">107.1&#x000b1;71.4</td><td valign="middle" align="center" rowspan="1" colspan="1">0.540</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">24 h-Drainage (ml)</td><td valign="middle" align="center" rowspan="1" colspan="1">186.9&#x000b1;101.4</td><td valign="middle" align="center" rowspan="1" colspan="1">188.3&#x000b1;110.0</td><td valign="middle" align="center" rowspan="1" colspan="1">0.927</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Hb drop (POD3)</td><td valign="middle" align="center" rowspan="1" colspan="1">27.2&#x000b1;10.4</td><td valign="middle" align="center" rowspan="1" colspan="1">29.0&#x000b1;10.2</td><td valign="middle" align="center" rowspan="1" colspan="1">0.230</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">HCT drop (POD3)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.08&#x000b1;0.02</td><td valign="middle" align="center" rowspan="1" colspan="1">0.09&#x000b1;0.03</td><td valign="middle" align="center" rowspan="1" colspan="1">0.222</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Transfusion rate</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pre-PT</td><td valign="middle" align="center" rowspan="1" colspan="1">11.6&#x000b1;1.4</td><td valign="middle" align="center" rowspan="1" colspan="1">11.4&#x000b1;0.7</td><td valign="middle" align="center" rowspan="1" colspan="1">0.265</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">PT (POD 1)</td><td valign="middle" align="center" rowspan="1" colspan="1">12.1&#x000b1;0.8</td><td valign="middle" align="center" rowspan="1" colspan="1">13.2&#x000b1;1.4</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">PT (POD 3)</td><td valign="middle" align="center" rowspan="1" colspan="1">12.0&#x000b1;0.9</td><td valign="middle" align="center" rowspan="1" colspan="1">12.6&#x000b1;1.2</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pre-APTT</td><td valign="middle" align="center" rowspan="1" colspan="1">28.2&#x000b1;4.7</td><td valign="middle" align="center" rowspan="1" colspan="1">29.1&#x000b1;5.9</td><td valign="middle" align="center" rowspan="1" colspan="1">0.206</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">APTT (POD 1)</td><td valign="middle" align="center" rowspan="1" colspan="1">33.5&#x000b1;5.2</td><td valign="middle" align="center" rowspan="1" colspan="1">39.0&#x000b1;8.4</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">APTT (POD 3)</td><td valign="middle" align="center" rowspan="1" colspan="1">36.4&#x000b1;6.4</td><td valign="middle" align="center" rowspan="1" colspan="1">40.1&#x000b1;7.7</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-medscimonit-23-704"><p>TBL &#x02013; total blood loss; HBL &#x02013; hidden blood loss; PT &#x02013; prothrombin time; APTT &#x02013; activated partial thromboplastin time.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-medscimonit-23-704" position="float"><label>Table 3</label><caption><p>Functional outcomes.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Variables</th><th valign="bottom" align="center" rowspan="1" colspan="1">Group A (n=98)</th><th valign="bottom" align="center" rowspan="1" colspan="1">Group B (n=96)</th><th valign="bottom" align="center" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">ROM at discharge</td><td valign="middle" align="center" rowspan="1" colspan="1">103.25&#x000b1;6.38</td><td valign="middle" align="center" rowspan="1" colspan="1">104.11&#x000b1;6.77</td><td valign="middle" align="center" rowspan="1" colspan="1">0.361</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">HSS at discharge</td><td valign="middle" align="center" rowspan="1" colspan="1">90.83&#x000b1;1.34</td><td valign="middle" align="center" rowspan="1" colspan="1">89.48&#x000b1;3.21</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">LOH (days)</td><td valign="middle" align="center" rowspan="1" colspan="1">6.1&#x000b1;1.7</td><td valign="middle" align="center" rowspan="1" colspan="1">6.3&#x000b1;2.9</td><td valign="middle" align="center" rowspan="1" colspan="1">0.729</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">VAS pain score (POD 1)</td><td valign="middle" align="center" rowspan="1" colspan="1">2.14&#x000b1;0.88</td><td valign="middle" align="center" rowspan="1" colspan="1">2.65&#x000b1;1.13</td><td valign="middle" align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">VAS pain score (POD 2)</td><td valign="middle" align="center" rowspan="1" colspan="1">2.07&#x000b1;0.46</td><td valign="middle" align="center" rowspan="1" colspan="1">2.31&#x000b1;0.80</td><td valign="middle" align="center" rowspan="1" colspan="1">0.013</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">VAS pain score (POD 3)</td><td valign="middle" align="center" rowspan="1" colspan="1">1.99&#x000b1;0.53</td><td valign="middle" align="center" rowspan="1" colspan="1">2.14&#x000b1;0.38</td><td valign="middle" align="center" rowspan="1" colspan="1">0.022</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">VAS pain score (POD 4)</td><td valign="middle" align="center" rowspan="1" colspan="1">1.95&#x000b1;0.42</td><td valign="middle" align="center" rowspan="1" colspan="1">2.12&#x000b1;0.33</td><td valign="middle" align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Swelling ratio</td><td valign="middle" align="center" rowspan="1" colspan="1">6 (6.1%)</td><td valign="middle" align="center" rowspan="1" colspan="1">16 (16.7%)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.021</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-medscimonit-23-704"><p>ROM &#x02013; range of motion; LOH &#x02013; length of hospital stay; HSS &#x02013; hospital for special surgery knee score; VAS &#x02013; visual analogue scale.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-medscimonit-23-704" position="float"><label>Table 4</label><caption><p>Complications.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Variables</th><th valign="bottom" align="center" rowspan="1" colspan="1">Group A (n=98)</th><th valign="bottom" align="center" rowspan="1" colspan="1">Group B (n=96)</th><th valign="bottom" align="center" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">DVT</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">0.121</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">CMVT</td><td valign="middle" align="center" rowspan="1" colspan="1">9 (9.2%)</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (2.1%)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.033</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">PE</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Mortality</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Readmission rate</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Major bleeding</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Minor bleeding (Ecchymosis)</td><td valign="middle" align="center" rowspan="1" colspan="1">10 (10.2%)</td><td valign="middle" align="center" rowspan="1" colspan="1">13 (13.5%)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.472</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Wound leakage</td><td valign="middle" align="center" rowspan="1" colspan="1">6 (6.1%)</td><td valign="middle" align="center" rowspan="1" colspan="1">11 (11.5%)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.189</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Hematoma</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">1</td><td valign="middle" align="center" rowspan="1" colspan="1">0.495</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Superficial infection</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">1</td><td valign="middle" align="center" rowspan="1" colspan="1">0.495</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Deep infection</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-medscimonit-23-704"><p>DVT &#x02013; deep venous thrombosis; CMVT &#x02013; calf muscular venous thrombosis; PE &#x02013; pulmonary embolism.</p></fn></table-wrap-foot></table-wrap></floats-group></article>